Inspection Checklist for Agent Special Requirements: 1918 Influenza, Poxvirus, RVFV, SARS-CoV, VEEV (42 CFR 73; BMBL 6th Edition)

Entity Name: **Inspection Date:**

Building/Rooms: **Inspectors:**

When information is entered in this form, the form is to be considered "Sensitive Select Agent Information."

Section	Regulation Text	Observation	Status	Comments
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	VEEV - HEPA filtration is required on the exhaust system of laboratory and animal facilities using VEE virus.	o No o Yes N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	RVFV - Personnel must use respiratory protection or be vaccinated for RVFV.	o No o Yes o N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	RVFV- HEPA filtration on laboratory exhaust is required for RVF virus.	o No o Yes o N/A	
12(a)	An individual or entity required to register under this part must develop and implement a written biosafety plan that is commensurate with the risk of the select agent or toxin, given its intended use. The biosafety plan must contain sufficient information and documentation to describe the biosafety and containment procedures for the select agent or toxin, including any animals (including arthropods) or plants intentionally or accidentally exposed to or infected with a select agent. The current biosafety plan must be submitted for initial registration, renewal of registration, or when requested.	Routine vaccination with ACAM2000 is recommended for laboratory personnel who directly handle cultures or animals contaminated or infected with repliction-competent vaccinia virus, recombinant vaccinia viruses derived from replication-competent vaccinia strains (i.e., those that are capable of causing clinical infection and producing infectious virus in humans), or other orthopoxviruses that infect humans (e.g., monkeypox, cowpox, and variola).	o No o Yes o N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	Routine vaccination with ACAM2000 is recommended for laboratory personnel who directly handle cultures or animals contaminated or infected with repliction-competent vaccinia virus, recombinant vaccinia viruses derived from replication-competent vaccinia strains (i.e., those that are capable of causing clinical infection and producing infectious virus in humans), or other orthopoxviruses that infect humans (e.g., monkeypox, cowpox, and variola).	o No o Yes o N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	To avoid inadvertent cross contamination of 1918 H1N1, HPAI H5N1 or human H2N2 (1957-1968): (2) Tissue cultures with these viruses shall be conducted at separate times (temporal spacing) in the same room.	o No o Yes o N/A	

Section	Regulation Text	Observation	Status	Comments
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	To avoid inadvertent cross contamination of 1918 H1N1, HPAI H5N1 or human H2N2 (1957-1968): (3) Separate reagents shall be used to minimize risk of cross contamination.	o No o Yes o N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	To avoid inadvertent cross contamination of 1918 H1N1, HPAI H5N1 or human H2N2 (1957-1968): (4) A laboratory worker shall not perform concurrent influenza virus experiments that carry the risk of unintended reassortment among 1918 H1N1, human H2N2 (1957-1968), HPAI H5N1 and other human influenza viruses.	o No o Yes o N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	To avoid inadvertent cross contamination of 1918 H1N1, HPAI H5N1 or human H2N2 (1957-1968): (5) Two or more laboratory workers shall not perform within the same work area simultaneous influenza virus experiments that carry the risk of unintended segment reassortment between 1918 H1N1, or HPAI H5N1, or human H2N2 (1957-1968) and other human influenza viruses.	o No o Yes o N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	To avoid inadvertent cross contamination of 1918 H1N1, HPAI H5N1 or human H2N2 (1957-1968): (6) Between experiments good biosafety decontamination practices (e.g., surface and biosafety cabinet surface decontamination according to standard BSL-3 procedures) shall be used and there shall be a thirty minute wait period after decontamination before equipment is used for experiments with any other influenza A viruses.	o No o Yes o N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	To avoid inadvertent cross contamination of 1918 H1N1, HPAI H5N1 or human H2N2 (1957-1968): (7) Between experiments, in addition to decontamination of the work area, clothing changes and PAPR disinfection shall be performed prior to handling a different influenza virus in the same work area. (Shower-out capability may be required by USDA/APHIS for certain experiments with HPAI H5N1.)	o No o Yes o N/A	
12(a)	An individual or entity required to register under this part must develop and implement a written biosafety plan that is commensurate with the risk of the select agent or toxin, given its intended use. The biosafety plan must contain sufficient information and documentation to describe the biosafety and containment procedures for the select agent or toxin, including any animals (including arthropods) or plants intentionally or accidentally exposed to or infected with a select agent. The current biosafety plan must be submitted for initial registration, renewal of registration, or when requested.	At a minimum, BSL-3 and ABSL-3 practices, procedures, and facilities must be used for work with reconstructed 1918 influenza virus.	o No o Yes o N/A	

Section	Regulation Text	Observation	Status	Comments
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	At a minimum, BSL-3 and ABSL-3 practices, procedures, and facilities must be used for work with reconstructed 1918 influenza virus.	o No o Yes o N/A	
12(a)	An individual or entity required to register under this part must develop and implement a written biosafety plan that is commensurate with the risk of the select agent or toxin, given its intended use. The biosafety plan must contain sufficient information and documentation to describe the biosafety and containment procedures for the select agent or toxin, including any animals (including arthropods) or plants intentionally or accidentally exposed to or infected with a select agent. The current biosafety plan must be submitted for initial registration, renewal of registration, or when requested.	Animals, including non-human primates should be housed in primary barrier systems in ABSL-3 facilities when working with reconstructed 1918 influenza virus.	o No o Yes o N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	Animals, including non-human primates should be housed in primary barrier systems in ABSL-3 facilities when working with reconstructed 1918 influenza virus.	o No o Yes o N/A	
12(a)	An individual or entity required to register under this part must develop and implement a written biosafety plan that is commensurate with the risk of the select agent or toxin, given its intended use. The biosafety plan must contain sufficient information and documentation to describe the biosafety and containment procedures for the select agent or toxin, including any animals (including arthropods) or plants intentionally or accidentally exposed to or infected with a select agent. The current biosafety plan must be submitted for initial registration, renewal of registration, or when requested.	For work with reconstructed 1918 influenza virus, personnel use negative pressure, HEPA-filtered respirators, or PAPRs.	o No o Yes o N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	For work with reconstructed 1918 influenza virus, personnel use negative pressure, HEPA-filtered respirators, or PAPRs.	o No o Yes o N/A	
12(a)	An individual or entity required to register under this part must develop and implement a written biosafety plan that is commensurate with the risk of the select agent or toxin, given its intended use. The biosafety plan must contain sufficient information and documentation to describe the biosafety and containment procedures for the select agent or toxin, including any animals (including arthropods) or plants intentionally or accidentally exposed to or infected with a select agent. The current biosafety plan must be submitted for initial registration, renewal of registration, or when requested.	For work with reconstructed 1918 influenza virus, personnel rigorously adhere to respiratory protection and clothing change protocols.	o No o Yes o N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	For work with reconstructed 1918 influenza virus, personnel rigorously adhere to respiratory protection and clothing change protocols.	o No o Yes o N/A	
12(a)	An individual or entity required to register under this part must develop and implement a written biosafety plan that is commensurate with the risk of the select agent or toxin, given its intended use. The biosafety plan must contain sufficient information and documentation to describe the biosafety and containment procedures for the select agent or toxin, including any animals (including arthropods) or plants intentionally or accidentally exposed to or infected with a select agent. The current biosafety plan must be submitted for initial registration, renewal of registration, or when requested.	Following work with reconstructed 1918 influenza virus, personnel shower prior to exiting the laboratory.	o No o Yes o N/A	

Section	Regulation Text	Observation	Status	Comments
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	Following work with reconstructed 1918 influenza virus, personnel shower prior to exiting the laboratory.	o No o Yes o N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	To avoid inadvertent cross contamination of 1918 H1N1, HPAI H5N1 or human H2N2 (1957-1968): (1) Containment facilities and practices appropriate for highest Risk Group virus shall be used at all times with lower Risk Group viruses, when studied in the same laboratory room.	o No o Yes o N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	Continued susceptibility of the reassortant influenza viruses containing genes and/or segments from 1918 H1N1, HPAI H5N1, and human H2N2 (1957-1968) to antiviral agents shall be established by sequence analysis or suitable biological assays. After manipulation of genes that influence sensitivity to antiviral agents, susceptibility to these agents shall be reconfirmed. If susceptibility to neuraminidase inhibitors or other effective antiviral agents is lost as a result of genetic modification or serial passage of a mammalian-transmissible HPAI H5N1 virus, then any research with this antiviral agent resistant virus shall be stopped and research shall only proceed after review by the NIH (as outlined in NIH Guidelines Section III-A-l-a) or the appropriate federal regulatory agency.	o No o Yes o N/A	
12(a)	An individual or entity required to register under this part must develop and implement a written biosafety plan that is commensurate with the risk of the select agent or toxin, given its intended use. The biosafety plan must contain sufficient information and documentation to describe the biosafety and containment procedures for the select agent or toxin, including any animals (including arthropods) or plants intentionally or accidentally exposed to or infected with a select agent. The current biosafety plan must be submitted for initial registration, renewal of registration, or when requested.	Institutions performing work with SARS-CoV or handling specimens likely to contain the agent should develop and implement a specific occupational medical plan with respect to this agent.	o No o Yes o N/A	

Section	Regulation Text	Observation	Status	Comments
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	Institutions performing work with SARS-CoV or handling specimens likely to contain the agent should develop and implement a specific occupational medical plan with respect to this agent.	o No o Yes o N/A	
12(b)	The biosafety and containment procedures must be sufficient to contain the select agent or toxin (e.g., physical structure and features of the entity, and operational and procedural safeguards).	When leaving the laboratory, employees follow the procedure(s) outlined in the plan and shower out at the non-containment/containment boundary.	o No o Yes o N/A	